Lobbying disclosures · Lobbying report
AMGN: second_quarter 2026 lobbying report
Issues related to Medicare and Medicaid drug pricing; Issues related to biosimilar access and affordability. Issues related to the 340B Program - Public Health Service Act (PL 78-410); Issues related to H.R. 5526/S. 1954 - Biosimilar Red Tape Elimination Act.
Follow AMGN- Became public
- Jul 19, 2026, 3:45 PM EDT
- Event / period date
- Not stated
- Collected
- Nov 8, 2026, 11:40 AM EST
Why this is connected
Exact legal-name match: AMGEN INC (https://www.sec.gov/Archives/edgar/data/318154/).
Reported lobbying amounts
Income: $60,000.00
These are different reporting measures. They are not added together or treated as spending on one particular bill.
Source evidence
Read the source excerpt or record
{"url":"https://lda.gov/api/v1/filings/2633ba3d-f28b-47bd-84f2-6f9295827ae6/","filing_uuid":"2633ba3d-f28b-47bd-84f2-6f9295827ae6","filing_type":"Q2","filing_type_display":"2nd Quarter - Report","filing_year":2026,"filing_period":"second_quarter","filing_period_display":"2nd Quarter (Apr 1 - June 30)","filing_document_url":"https://lda.gov/filings/public/filing/2633ba3d-f28b-47bd-84f2-6f9295827ae6/print/","filing_document_content_type":"text/html","income":"60000.00","expenses":null,"expenses_method":null,"expenses_method_display":null,"posted_by_name":"Jonathon Jones, Partner","dt_posted":"2026-07-19T15:45:23-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"750 9th Street NW","registrant_address_2":"Suite 501","registrant_different_address":false,"registrant_city":"Washington","registrant_state":"DC","registrant_zip":"20001","registrant":{"id":20744,"url":"https://lda.gov/api/v1/registrants/20744/","house_registrant_id":31587,"name":"TIBER CREEK GROUP","description":"Government Relations.","address_1":"750 9th Street NW","address_2":"Suite 501","address_3":null,"address_4":null,"city":"Washington","state":"DC","state_display":"District of Columbia","zip":"20001","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"GRACE BAUM","contact_telephone":"+1 202-381-6896","dt_updated":"2026-07-20T13:07:00.819992-04:00"},"client":{"id":127116,"url":"https://lda.gov/api/v1/clients/127116/","client_id":1000492,"name":"AMGEN INC","general_description":null,"client_government_entity":false,"client_self_select":null,"state":"DC","state_display":"District of Columbia","country":"US","country_display":"United States of America","ppb_state":null,"ppb_state_display":null,"ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2007-08-13"},"lobbying_activities":[{"general_issue_code":"MMM","general_issue_code_display":"Medicare/Medicaid","description":"Issues related to Medicare and Medicaid drug pricing; Issues related to biosimilar access and affordability.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":26450,"prefix":null,"prefix_display":null,"first_name":"JONATHON","nickname":null,"middle_name":null,"last_name":"JONES","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":47178,"prefix":null,"prefix_display":null,"first_name":"JOHN","nickname":null,"middle_name":"MICHAEL","last_name":"GONZALEZ","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":107185,"prefix":null,"prefix_display":null,"first_name":"COREY","nickname":null,"middle_name":null,"last_name":"MALMGREN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":143334,"prefix":"mr","prefix_display":"MR.","first_name":"DANIEL","nickname":null,"middle_name":"HOWARD","last_name":"ZAWITOSKI","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"Issues related to the 340B Program - Public Health Service Act (PL 78-410); Issues related to H.R. 5526/S. 1954 - Biosimilar Red Tape Elimination Act.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":26450,"prefix":null,"prefix_display":null,"first_name":"JONATHON","nickname":null,"middle_name":null,"last_name":"JONES","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":47178,"prefix":null,"prefix_display":null,"first_name":"JOHN","nickname":null,"middle_name":"MICHAEL","last_name":"GONZALEZ","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":107185,"prefix":null,"prefix_display":null,"first_name":"COREY","nickname":null,"middle_name":null,"last_name":"MALMGREN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":143334,"prefix":"mr","prefix_display":"MR.","first_name":"DANIEL","nickname":null,"middle_name":"HOWARD","last_name":"ZAWITOSKI","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]}Congressional trading in AMGN
These disclosures provide context. Their presence does not establish a link between a trader and the event.
- Nov 2, 2026$15K–$50K
Sen. Sheldon Whitehouse (D-RI)
$15K–$50K · Traded Oct 15, 2026 · disclosed Nov 2, 2026 · Spouse
Committee overlap: Finance - Oct 7, 2026$1K–$15K
Rep. Ro Khanna (D-CA-17)
$1K–$15K · Traded Sep 4, 2026 · disclosed Oct 7, 2026 · Spouse
- Oct 1, 2026$1K–$15K
Rep. David J. Taylor (R-OH-2)
$1K–$15K · Traded Sep 22, 2026 · disclosed Oct 1, 2026
- Sep 5, 2026$1K–$15K
- Sep 5, 2026$1K–$15K
- Sep 2, 2026$1K–$15K
Sen. Sheldon Whitehouse (D-RI)
$1K–$15K · Traded Aug 12, 2026 · disclosed Sep 2, 2026 · Spouse
Committee overlap: Finance - Jul 21, 2026$15K–$50K
Sen. Alan Armstrong (R-OK)
$15K–$50K · Traded Mar 27, 2026 · disclosed Jul 21, 2026 · filed 116 days later
Committee overlap: HELP - Jun 12, 2026$1K–$15K
Rep. David J. Taylor (R-OH-2)
$1K–$15K · Traded Jun 5, 2026 · disclosed Jun 12, 2026
Original documents control. Public records can be amended, and company connections may require interpretation. Nothing here is investment advice.